Mereo Biopharma Group Plc ADR (NASDAQ: MREO) closed the day trading at $2.97 down -0.34% from the previous closing price of $2.98. In other words, the price has decreased by -$0.0100 from its previous closing price. On the day, 1307596 shares were traded.
Ratios:
For a better understanding of MREO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.08.
On August 12, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $4.
On May 05, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $10.BTIG Research initiated its Buy rating on May 05, 2021, with a $10 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MREO now has a Market Capitalization of 420.73M and an Enterprise Value of 379.20M. For the stock, the TTM Price-to-Sale (P/S) ratio is 43.38 while its Price-to-Book (P/B) ratio in mrq is 5.19. Its current Enterprise Value per Revenue stands at 53.20 whereas that against EBITDA is -15.49.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $4.36, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 3.5345, while the 200-Day Moving Average is calculated to be 2.1116.
Shares Statistics:
Over the past 3-months, MREO traded about 1.77M shares per day on average, while over the past 10 days, MREO traded about 1.39M shares per day. A total of 128.39M shares are outstanding, with a floating share count of 128.39M. Insiders hold about 0.00% of the company’s shares, while institutions hold 66.97% stake in the company. Shares short for MREO as of Feb 29, 2024 were 2.23M with a Short Ratio of 1.26, compared to 2.21M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.59% and a Short% of Float of 2.21%.
Earnings Estimates
Current recommendations for the stock of the company come from 0 analysts. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
